オプションチェーンは、Mira Pharmaceuticalsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Mira Pharmaceuticalsの市場センチメントを評価します。.

Mira Pharmaceuticals (NASDAQ:MIRA) 株価情報, オプションチェーン

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRATI THERAPEUTICS INC COM

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

Miratap Inc

MIRAVANT MEDICAL TECHS by Miravant Medical Technologies

Miravant Medical Technologies

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">234.7200</td>
<td align="right">3.480</td>
<td align="right">1.50</td>
<td>89.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">216.8205</td>
<td align="right">1.941</td>
<td align="right">0.90</td>
<td>7.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">102.2800</td>
<td align="right">0.480</td>
<td align="right">0.47</td>
<td>5.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">142.9700</td>
<td align="right">0.370</td>
<td align="right">0.25</td>
<td>13.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">81.7873</td>
<td align="right">0.137</td>
<td align="right">0.16</td>
<td>75.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.6600</td>
<td align="right">0.070</td>
<td align="right">0.13</td>
<td>334.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">131.5000</td>
<td align="right">0.020</td>
<td align="right">0.01</td>
<td>18.8K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.20</td>
<td align="right">-0.11</td>
<td align="right">-0.27</td>
<td>2.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.58</td>
<td align="right">-0.20</td>
<td align="right">-0.25</td>
<td>43.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.48</td>
<td align="right">-0.05</td>
<td align="right">-0.07</td>
<td>5.0K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For May 29, 2025

Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) shares are trading higher in the premarket session on Thursday after the company beat earnings <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45656415/veeva-announces-fiscal-2026-first-quarter-results" rel="noreferrer noopener">in the first quarter and raised the outlook.</a>
In the after-market session on Wednesday, the company reported adjusted earnings per share of $1.97, beating the analyst consensus estimate of $1.77. Quarterly sales of $759 million (+17% year over year) outpaced the Street view of $731.91 million.
&#8220;We crossed our 2025 revenue run rate goal this quarter and are progressing well toward our 2030 goal to double that and the positive impact we can have for our customers and the industry,&#8221; said CFO Brian Van Wagener. 
Also Read: <a target="_blank" href="https://www.benzinga.com/general/market-summary/25/05/45604787/cathie-wood-reiterates-profound-ai-application-in-healthcare-as-researchers-discover-cancer-survival-outcomes-by-facial-photograph-analysis-here-are-the-stocks-that-could-benefit" rel="noreferrer noopener">Cathie Wood Reiterates &#8216;Profound&#8217; AI Application In Healthcare As Researchers Discover &#8216;Cancer Survival Outcomes&#8217; By Facial Photograph Analysis: Here Are The Stocks That Could Benefit</a>
Subscription services revenues for the first quarter were&nbsp;$634.8 million, an increase of 19% year over year.
Quarterly adjusted operating income for the first quarter jumped 34% year over year to&nbsp;$349.9 million.
Outlook: For the fiscal second quarter ending July 31, Veeva expects total revenue between $766 million and $769 million (Street View: $765.34 million), non-GAAP operating income between $335 million and $337 million and adjusted diluted EPS between $1.89 and $1.90 (Street view: $1.88).
For the full fiscal year ending January 31, 2026, the company projects total revenue between $3.09 billion and $3.10 billion versus the Street view of $3.09 billion (<a href="https://ir.veeva.com/investors/news-and-events/latest-news/press-release-details/2025/Veeva-Announces-Fourth-Quarter-and-Fiscal-Year-2025-Results/default.aspx" target="_blank" rel="noopener">prior view:</a> $3.040 billion to $3.055 billion), non-GAAP operating income of approximately $1.36 billion, and adjusted diluted EPS of around $7.63 versus the Street view of $7.56 (Prior view: $7.32).
Price Action: VEEV shares are trading higher by 14.6% to $268.65 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45664142/why-nvidia-shares-are-trading-higher-by-over-5-here-are-20-stocks-moving-premarket" target="_blank" rel="noreferrer noopener">Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket</a></li>
</ul>
Photo: Shutterstock

Equities

News

Markets

General

VEEV

Why Veeva Systems Stock Is Gaining Today

<a href="https://www.nytimes.com/2025/05/29/business/media/new-york-times-amazon-ai-licensing.html" title="https://www.nytimes.com/2025/05/29/business/media/new-york-times-amazon-ai-licensing.html">https://www.nytimes.com/2025/05/29/business/media/new-york-times-amazon-ai-licensing.html</a>

AMZN

'The Times And Amazon Announce A.I. Licensing Deal' - NY Times

Wells Fargo analyst Stephen Baxter upgrades HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Underweight to Equal-Weight and raises the price target from $320 to $385.

Upgrades

Price Target

Analyst Ratings

Wells Fargo Upgrades HCA Healthcare to Equal-Weight, Raises Price Target to $385

Silexion Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced compelling preclinical data demonstrating the efficacy of its next-generation RNAi therapeutic candidate, SIL204, against human pancreatic, colorectal and lung (NSCLC) cancer cell lines. These results significantly expand SIL204's therapeutic potential beyond pancreatic cancer, allowing it to potentially address major KRAS-driven cancers with substantial unmet medical needs.
Following the Company's recent announcement of completion of preclinical studies, a comprehensive analysis of the data has revealed that SIL204 effectively inhibited the proliferation and metabolic activity of human cancer cell lines harboring KRAS G12D mutations across multiple cancer types, resulting in the following obvervations:
<ul>
<li>The data reveals SIL204 successfully inhibited the proliferation and metabolic activity of human cancer cell lines harboring a specific KRAS mutation (G12D): GP2D (colorectal), A427 (lung) and Panc-1 (pancreatic), in a statistically significant manner.</li>
<li>The significant inhibition was observed in a dose-dependent manner down to nanomolar concentrations.</li>
<li>As observed in the left hand graph below (figure 1), a dose-dependent reduction in cell viability was noted in GP2D colorectal cancer cells, even in the absence of external additives, due to the lipid end of SIL204.</li>
<li>Notably, as can be seen in the right hand graph below (figure 2), the Company observed an inhibition rate of approximately 90% in the presence of SIL204 in GP2D colorectal cancer cells.</li>
</ul>
The Company plans to conduct an additional study focused on the inhibition effects of SIL204 on lung (NSCLC) cancer cell lines (A427) in the coming weeks to uncover further data.

Biotech

SLXN

Silexion Therapeutics Announces Preclinical Results For RNAi Candidate SIL204, Showing Potent Efficacy Against KRAS G12D-Driven Pancreatic, Colorectal, And Lung Cancers

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares are rising Thursday after the company beat expectations for the first quarter, boosted by a continued acceleration of its data center business. Multiple analysts reiterated Buy ratings or lifted price targets <a href="https://www.benzinga.com/markets/25/05/45661128/ross-gerber-blasts-trump-for-destroying-nvidias-china-business-gene-munster-says-forget-about-the-china-curbs-because-the-chip-giants-co">following the print</a>.
Q1 Earnings: Nvidia reported first-quarter revenue of $44.06 billion, beating analyst estimates of $43.21 billion. The company reported adjusted earnings of 81 cents. Excluding the charges related to restrictions on chip sales to China, adjusted earnings was 96 cents per share, which was stronger than analysts were anticipating, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 69% on a year-over-year basis. Here&#8217;s a breakdown of revenue by segment:
<ul class="wp-block-list">
<li>Data center revenue: $39.1 billion, up 73%</li>
</ul>
<ul class="wp-block-list">
<li>Gaming &amp; AI PC revenue: $3.8 billion, up 42%</li>
</ul>
<ul class="wp-block-list">
<li>Professional Visualization revenue: $509 million, up 19%</li>
</ul>
<ul class="wp-block-list">
<li>Automotive &amp; Robotics revenue: $567 million, up 72%</li>
</ul>
Nvidia said it will pay its next quarterly cash dividend of one cent per share on July 3 to shareholders of record as of June 11.
&#8220;Global demand for NVIDIA&#8217;s AI infrastructure is incredibly strong. AI inference token generation has surged tenfold in just one year, and as AI agents become mainstream, the demand for AI computing will accelerate. Countries around the world are recognizing AI as essential infrastructure — just like electricity and the internet — and NVIDIA stands at the center of this profound transformation,&#8221; said Jensen Huang, founder and CEO of Nvidia.
Check This Out: <a href="https://www.benzinga.com/media/25/05/45664231/teslas-optimus-may-be-the-first-humanoid-robot-to-achieve-high-volume-and-tech-scale-says-nvidia-ceo-jensen-huang-likely-to-be-the-next-multi-trillion-dollar-industry">Tesla&#8217;s Optimus May Be The First Humanoid Robot To Achieve High Volume And Tech Scale, Says Nvidia CEO Jensen Huang: &#8216;&#8230; Likely To Be The Next Multi-Trillion Dollar Industry&#8217;</a>
Guidance: Nvidia forecasted second-quarter revenue of $45 billion, plus or minus 2%, versus <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates of $45.78 billion. The company noted that its outlook reflects a loss of approximately $8 billion in H20 revenue due to the export control limitations. 
Huang stressed the importance of the Chinese market on a conference call following the company&#8217;s quarterly results. The Nvidia CEO told investors and analysts that whoever wins China will be positioned to lead globally.
Analysts React To Q1: Multiple analysts reiterated <a href="https://www.benzinga.com/analyst-stock-ratings">Buy ratings</a> on Nvidia following the print with some raising price targets ranging from $160 to $200. 
Wedbush&#8217;s Dan Ives <a href="https://x.com/DivesTech/status/1928006767289495901">predicted</a> that Nvidia is on a path to a $4 trillion market cap, eventually reaching $5 trillion as the company benefits from increasing AI spend over the coming years. He <a href="https://x.com/DivesTech/status/1927845077554004286">noted</a> that the AI chip giant delivered another &#8220;robust&#8221; quarter with &#8220;solid&#8221; guidance. 
Deepwater&#8217;s Gene Munster<a href="https://www.benzinga.com/markets/25/05/45661128/ross-gerber-blasts-trump-for-destroying-nvidias-china-business-gene-munster-says-forget-about-the-china-curbs-because-the-chip-giants-co"> said</a> Nvidia&#8217;s core business is on fire and &#8220;off the charts good.&#8221; He highlighted impressive growth when excluding the impacts of the China chip restrictions. 
&#8220;If you back out the impact of the curbs, YoY revenue growth in April would have been 79% (reported 69%). Guide for July would have been 76% (actual guide with curbs 50%). That fractional decline of revenue growth quarter over quarter off of a much bigger base is impressive, and the latest evidence that the company&#8217;s growth will be higher for longer,&#8221; Munster <a href="https://x.com/munster_gene/status/1927830126957392255">said</a>.
NVDA Price Action: <a href="http://benzinga.com/quote/nvda">Nvidia shares</a> were up 5.55% at $142.34 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45668187/nvidia-faces-bipartisan-backlash-over-its-shanghai-facility-amid-significant-national-and-economic-security-threat-report">Nvidia Faces Bipartisan Heat Over Its Shanghai Facility Amid &#8216;Significant&#8217; National And Economic Security Threat: Report</a></li>
</ul>
Photo: Hepha1st0s/Shutterstock.

Earnings

Guidance

NVDA

Nvidia Stock Is Surging Thursday: What's Fueling The Move?

DDC Enterprise Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDC#NYSE">DDC</a>) today announced the acquisition of 79 Bitcoin (BTC) as part of its ongoing Bitcoin accumulation strategy. This strategic purchase reinforces DDC's commitment to leveraging Bitcoin's scarcity-driven value proposition as a core component of its treasury reserve portfolio. DDC issued 580,187 class A ordinary shares in exchange for the new BTC purchase. BTC per 1,000 DDC shares increased from 0.006122 to 0.024963, up 400%.
In tandem with this acquisition, DDC has entered into a partnership with Hex Trust, a globally recognized digital asset financial institution specializing in institutional-grade custody, staking, and markets services. As one of the key custodians within DDC's newly established dynamic custodian network, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fhextrust.com%2Fconsensus2025&amp;esheet=54262002&amp;newsitemid=20250529303628&amp;lan=en-US&amp;anchor=Hex+Trust&amp;index=1&amp;md5=0220270d4a81bc198ca24f22ddd8237a">Hex Trust</a> will provide institutional-grade custody and trading execution services , designed to ensure the security and scalability of the Company's rapidly growing Bitcoin holdings.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

DDC Enterprise Acquires 79 Bitcoin Via Share Exchange And Partners With Hex Trust For Institutional-Grade Custody And Trading Services

Wells Fargo analyst Stephen Baxter upgrades Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Equal-Weight to Overweight and raises the price target from $150 to $195.

Wells Fargo Upgrades Tenet Healthcare to Overweight, Raises Price Target to $195

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Bernstein raised Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) price target from $243 to $255. Bernstein analyst Mark Moerdler maintained an Underperform rating. Salesforce shares closed at $276.03 on Wednesday. <a href="https://www.benzinga.com/quote/CRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan cut the price target for SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) from $22 to $19. JP Morgan analyst Brian Essex downgraded the stock from Overweight to Neutral. SentinelOne shares closed at $19.67 on Wednesday. <a href="https://www.benzinga.com/quote/S/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays cut Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) price target from $13 to $7. Barclays analyst David Anderson downgraded the stock from Overweight to Equal-Weight. Aspen Aerogels shares closed at $6.42 on Wednesday. <a href="https://www.benzinga.com/quote/ASPN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies increased the price target for GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) from $427 to $517. Jefferies analyst Julien Dumoulin-Smith downgraded the stock from Buy to Hold. GE Vernova shares closed at $485.01 on Wednesday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital cut the price target for Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) from $420 to $275. RBC Capital analyst Rishi Jaluria downgraded the stock from Outperform to Sector Perform. Salesforce shares closed at $276.03 on Wednesday. <a href="https://www.benzinga.com/quote/CRM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James cut Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) price target from $130 to $110. Raymond James analyst Srini Pajjuri maintained an Outperform rating. Marvell Technology shares settled at $64.59 on Wednesday. <a href="https://www.benzinga.com/quote/MRVL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group slashed Macy&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) price target from $15 to $14. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Macy&#8217;s shares closed at $12.00 on Wednesday. <a href="https://www.benzinga.com/quote/M/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt boosted NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) price target from $178 to $200. Rosenblatt analyst Kevin Cassidy maintained a Buy rating. Nvidia shares closed at $134.81 on Wednesday.  <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised the price target for Veeva Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NASDAQ">VEEV</a>) from $270 to $300. Needham analyst Ryan MacDonald maintained a Buy rating. Veeva shares settled at $234.49 on Wednesday. <a href="https://www.benzinga.com/quote/VEEV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ascendiant Capital slashed Banzai International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) price target from $26 to $24. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Banzai International shares closed at $0.9975 on Wednesday. <a href="https://www.benzinga.com/quote/BNZI/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NVDA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29090416/image-390-1024x572.png" alt="" class="wp-image-931574" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29090416/image-390-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29090416/image-390-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29090416/image-390-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29090416/image-390.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative">Jim Cramer Says This Quantum Computing Stock Is &#8216;So High&#8217; And &#8216;Too Speculative&#8217;</a> </li>
</ul>
Photo via Shutterstock

Trading Ideas

ASPN

BNZI

MRVL

Nvidia To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Thursday

HeartSciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to enable earlier detection of heart disease, today announced the signing of its first commercial customer for the MyoVista Insights&#x2122; platform: Westcliffe Health Innovations, based in the United Kingdom.
This milestone follows the recent launch of MyoVista Insights and the initiation of an early adopter program for reference sites earlier this month.

Contracts

HSCS

HeartSciences Signs First Commercial Customer, Westcliffe Health Innovations UK, For Its AI-Powered MyoVista Insights Platform

Specialty athletic retailer&nbsp;Foot Locker Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45665097/foot-locker-inc-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">first-quarter results</a> on Thursday.
Last week, Foot Locker disclosed a definitive deal to be acquired by Dick's Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>), which values Foot Locker's equity at around $2.4 billion and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45431136/dicks-sporting-goods-to-acquire-foot-locker-to-create-a-global-leader-in-the-sports-retail-industr" rel="noreferrer noopener">its enterprise at about $2.5 billion</a>.
The company reported a quarterly sales decline of 4.6% year-on-year to $1.79 billion, missing the analyst&nbsp;consensus estimate of $1.89 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45477478/whats-next-for-foot-locker-analyst-says-dicks-deal-is-timely" rel="noreferrer noopener">What's Next For Foot Locker? Analyst Says Dick's Deal Is Timely</a>
Comparable store sales decreased 2.6% compared to last year. Adjusted EPS of 7 cents loss missed the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst consensus estimate</a> of 14 cents.
The gross margin declined by 40 basis points, merchandise margins decreased by 10 basis points, and occupancy as a percentage of sales increased by 30 basis points compared to the prior-year period.
Selling, general, and administrative expenses remained flattish Y/Y at $458 million.
Loss from operations for the quarter was $271 million. Merchandise inventories were $1.67 billion, flattish Y/Y.
The company held $343 million in cash and equivalents as of May 3, 2025. It used $3 million in operating cash flow during the quarter.
During the first quarter, the company opened nine&nbsp;new stores&nbsp;and closed 56&nbsp;stores in&nbsp;South Korea,&nbsp;Denmark,&nbsp;Norway,&nbsp;Sweden,&nbsp;Greece, and&nbsp;Romania. It also remodeled or relocated 11&nbsp;stores and refreshed 69.
As of&nbsp;May 3, 2025, the company operated 2,363&nbsp;stores in 20&nbsp;North American, European, Asian, Australian, and&nbsp;New Zealand countries. In addition, 236 licensed stores were operating in the&nbsp;Middle East,&nbsp;Europe, and&nbsp;Asia.
Mary Dillon, CEO, said the company continued to execute its Lace Up Plan strategies as it looked forward to the successful completion of its transaction with DICK'S Sporting Goods.&nbsp;He acknowledged that when it reported preliminary first-quarter results, it experienced softer traffic trends globally that impacted its performance.&nbsp;
Price Action: At the last check on Thursday, FL shares were trading higher by 0.08% to $23.92 in the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45476123/analyst-sees-long-term-gain-for-dicks-with-foot-locker-despite-investor-skepticism" target="_blank" rel="noreferrer noopener">Dick's Foot Locker Move Draws Skepticism As Analysts Question Game Plan</a></li>
</ul>
Photo by BCFC via Shutterstock

Foot Locker Quarterly Sales Slip Following Acquisition Deal

Bath &amp; Body Works Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) shares traded higher in premarket on Thursday after the company reported <a href="https://www.benzinga.com/pressreleases/25/05/g45665432/bath-body-works-reports-2025-first-quarter-results-and-maintains-fiscal-year-2025-guidance" target="_blank" rel="noreferrer noopener">first-quarter fiscal 2025</a> results.
The company posted a 2.9% year-over-year increase in sales to $1.42 billion, which is in line with analyst expectations. Earnings per share rose to 49 cents from 38 cents a year ago, topping the consensus estimate of 46 cents.
Gross profit rose 6.6% year over year to $646 million, with gross margin improving 160 basis points to 45.4%. Operating income climbed 11.8% to $209 million, with an operating margin of 14.7%.
Bath &amp; Body Works held $636 million in cash and equivalents as of May 3, 2025. At the end of the quarter, inventories increased 6.8% YoY to $869 million.
The operating cash flow for the quarter totaled $188 million, up from $86 million a year ago.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45518304/these-analysts-boost-their-forecasts-on-bath-body-works" rel="noreferrer noopener">These Analysts Boost Their Forecasts On Bath &amp; Body Works</a>
&#8220;Our team delivered a strong start to the year driven by the positive customer response to our innovation in the quarter. We&#8217;re effectively leveraging our predominantly U.S.-based supply chain to navigate the evolving trade environment, and I&#8217;m confident in our ability to adapt to meet the consumer where they are with fragrance innovation and high-quality product at compelling price points as we move through 2025,&#8221; said Eva Boratto, CFO of Bath &amp; Body Works.  
Last week, the company announced that its independent directors unanimously <a href="https://www.benzinga.com/pressreleases/25/05/g45491656/bath-body-works-appoints-daniel-heaf-as-chief-executive-officer" target="_blank" rel="noreferrer noopener">appointed</a> Daniel Heaf as CEO, effective May 16, 2025. Following the 2025 Annual Meeting of Shareholders, Heaf was also appointed to the Board of Directors.
Outlook: Bath &amp; Body Works reaffirmed its full-year 2025 outlook, projecting net sales growth of 1% to 3% and earnings per share between $3.25 and $3.60 versus the consensus of $3.57. The forecast includes the impact of current tariffs and $300 million in planned share repurchases.
Free cash flow is expected to range from $750 million to $850 million.
For the second quarter, the company expects flat to 2% sales growth and EPS of $0.33 to $0.38 versus the consensus of $0.42, including tariff impacts. Guidance excludes the estimated $0.05 per share impact from the CEO transition.
Price Action: At last check Thursday, BBWI shares were trading higher by 2.53% at $31.25 in the premarket.
Read Next:
<a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45667660/costco-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-2" rel="noreferrer noopener">Costco Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>
Photo: Shutterstock

BBWI

Bath & Body Works Beats Q1 Estimates, Reaffirms Outlook As New CEO Steps In

IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end
BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonists Internally discovered compound has a novel binding site and potential best-in-class profile supporting once daily dosing

BIOA

BioAge Labs Completes IND-Enabling Studies For BGE-102 And Advances Candidate Toward Clinic

Wells Fargo analyst Andrew Nowinski downgrades SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) from Overweight to Equal-Weight and lowers the price target from $22 to $18.

Downgrades

Wells Fargo Downgrades SentinelOne to Equal-Weight, Lowers Price Target to $18

EGHT

8x8 Inc. Promotes Creovai To SoldBy8 Tier Within 8x8 Technology Partner Ecosystem

C3 AI Announces US Air Force Has Raised Contract Ceiling To $450M Through Oct. 2029

WIIM

SAGT

SAGT stock has given up its prior gain. SAGTEC GLOBAL shares were trading higher after the company announced its intent to acquire Smart Bridge.

TENB

Tenable To Acquire Apex Security, Terms Not Disclosed

Expansion builds on the companies' successful collaboration in the U.S., further underscoring the value of Affirm's flexible and transparent pay-over-time options across borders
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.affirm.com%2Fen-ca%2F&amp;esheet=54261752&amp;newsitemid=20250529904934&amp;lan=en-US&amp;anchor=Affirm&amp;index=1&amp;md5=5e75075ef7f2dcccabe0dd84b2a66fff">Affirm</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), the payment network that empowers consumers and helps merchants drive growth, today announced the expansion of its partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.williams-sonomainc.com&amp;esheet=54261752&amp;newsitemid=20250529904934&amp;lan=en-US&amp;anchor=Williams-Sonoma%2C+Inc.&amp;index=2&amp;md5=3fa8fb735e8f21553132e677da8df6b6">Williams-Sonoma, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) into Canada. This builds on the companies' multi-year partnership in the U.S. and brings Affirm to Canadians shopping at Williams-Sonoma, Inc.'s family of brands including Williams Sonoma, West Elm, Pottery Barn, Pottery Barn Teen, Pottery Barn Kids, and Mark &amp; Graham.
Whether shopping for a sofa at their local West Elm or furnishing a new nursery with Pottery Barn Kids, approved Canadian shoppers can now split their purchases into monthly payments with Affirm. The process is simple: after selecting Affirm at checkout, consumers go through a quick, real-time eligibility check. If approved, they can choose the customized payment plan that best suits their needs and rest assured that they will never pay any late or hidden fees.

AFRM

Affirm Expands Partnership With Williams-Sonoma Into Canada, Extending Flexible Payment Options

Stock Split

MULN

Mullen Automotive Announces 1-For-100 Reverse Stock Split

Press Releases

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

MIRA

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Gelteq

Grace Therapeutics

IGC Pharma

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

Lipocine

ProPhase Labs

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Scilex Holding

SCYNEXIS

TherapeuticsMD

VYNE Therapeutics

Rodman & Renshaw

Ascendiant Capital

Screenshot 2024-10-02 at 5.44.40 PM

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Screenshot 2024-09-18 at 6.27.57 PM

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

Screenshot 2024-09-04 at 6.19.41 PM

TELO

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-08-26 at 4.53.37 PM

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Screenshot 2024-07-25 at 6.08.16 PM

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Comments

Mira Pharmaceuticals

Mira Pharmaceuticals (MIRA) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル